Nephrology Department, Regional University Hospital of Malaga, Malaga, Spain.
Nephrology Department, Regional University Hospital of Malaga, Malaga, Spain.
Transplant Proc. 2022 Jan-Feb;54(1):25-26. doi: 10.1016/j.transproceed.2021.09.063. Epub 2021 Dec 12.
The atypical hemolytic-uremic syndrome (aHUS) is characterized by the triad of non-immune hemolytic anemia, thrombocytopenia, and acute renal failure. The aHUS is related to complement dysregulation; since the approval of eculizumab for this entity (a monoclonal antibody that inhibits C5 activation and blocks the formation of the membrane attack complex) the prognosis has improved. The recurrence of aHUS after kidney transplantation is frequent and implies loss of the graft in a high percentage of cases. Eculizumab prophylaxis to prevent recurrence has allowed successful kidney transplantation in this group of patients. We present a series of kidney transplant patients with chronic kidney disease secondary to aHUS and the use of eculizumab for prevention of recurrence.
非典型溶血性尿毒综合征（aHUS）的特征是三联征：非免疫性溶血性贫血、血小板减少和急性肾衰竭。aHUS 与补体失调有关；自依库珠单抗（一种抑制 C5 活化并阻断膜攻击复合物形成的单克隆抗体）获批用于该疾病以来，预后得到改善。肾移植后 aHUS 的复发较为常见，并且在很大比例的病例中会导致移植物丢失。依库珠单抗预防复发已使得这组患者的肾移植获得成功。我们介绍了一组继发于 aHUS 的慢性肾脏病肾移植患者，以及使用依库珠单抗预防复发的情况。
